The neuroprotective efficacy of MK-801 in focal cerebral ischemia varies with rat strain and vendor.

Abstract

The present study was designed to evaluate whether the neuroprotective efficacy of MK-801 in focal cerebral ischemia was dependent on strain and/or vendor differences. MK-801 (0.12 mg/kg i.v. bolus followed by 0.108 mg/kg/h infusion or 0.60 mg/kg i.v. bolus followed by 0.540 mg/kg/h infusion) or saline was administered just after intraluminal middle cerebral artery occlusion. Administration of 0.540 mg/kg/h MK-801 provided strain/line-dependent neuroprotection in the following rank order: Simonsen Laboratories Sprague-Dawley rats > Simonsen Laboratories Wistar rats > Taconic Laboratories Sprague-Dawley rats. After 0.108 mg/kg/h MK-801 treatment, Simonsen Laboratories Wistar rats were the only strain/line that were significantly neuroprotected. These results indicate that the neuroprotective effect of an experimental drug may be influenced by rat strain and vendor differences.

• Authors: H S Oliff, P Marek, B Miyazaki, E Weber
• Journal: Brain research (Brain Res) Vol. 731 Issue 1-2 Pg. 208-12 (Aug 26 1996) ISSN: 0006-8993 [Print] Netherlands
• PMID: 8883872 (Publication Type: Comparative Study, Journal Article, Research Support, U.S. Gov't, P.H.S.)

Chemical References

• Neuroprotective Agents
• Dizocilpine Maleate

Topics

• Animals
• Animals, Laboratory
• Body Temperature (drug effects)
• Brain Ischemia (drug therapy)
• Cerebral Arteries (surgery)
• Cerebral Cortex (blood supply, drug effects, physiopathology)
• Dizocilpine Maleate (pharmacology)
• Dose-Response Relationship, Drug
• Ligation
• Male
• Neuroprotective Agents (pharmacology)
• Rats
• Rats, Sprague-Dawley
• Rats, Wistar